| Date |
Title |
| Dec 23, 2021 |
Illumina To Webcast Upcoming Investor Conference |
| Dec 9, 2021 |
Illumina Supports Norway's Pioneering Precision Medicine Study |
| Nov 17, 2021 |
Illumina and Sequoia Capital China Select First Startups to join Genomics Incubator in China |
| Nov 16, 2021 |
Illumina and Genetic Alliance Launch $120 Million Global Initiative to Increase Equity and Improve Outcomes for Families Impacted by Genetic Disease |
| Nov 4, 2021 |
Illumina Reports Financial Results for Third Quarter of Fiscal Year 2021 |
| Nov 3, 2021 |
Illumina Supports Canada's Nationwide COVID-19 Genome Sequencing Initiative |
| Oct 27, 2021 |
Illumina Supports Israel's National Program to Accelerate Diagnoses of Critically-Ill Newborns with Suspected Genetic Disease |
| Oct 20, 2021 |
Illumina to Host Inaugural ESG Investor Event on Tuesday, November 16, 2021 |
| Oct 14, 2021 |
Illumina Appoints Bob Ragusa as Chief Executive Officer (CEO) of GRAIL |
| Oct 13, 2021 |
Illumina to Announce Third Quarter 2021 Financial Results on Thursday, November 4, 2021 |
| Sep 30, 2021 |
Illumina Expands Presence in Latin America |
| Sep 27, 2021 |
Randomized trial demonstrates whole-genome sequencing leads to precision care for critically ill infants |
| Sep 15, 2021 |
Illumina Accelerator Invests in Seven Genomics Startups for Third Global Cycle |
| Sep 9, 2021 |
Illumina Commits to Net Zero Global Greenhouse Gas Emissions by 2050 |
| Sep 7, 2021 |
Illumina Partners with Merck to Develop and Commercialize Companion Diagnostic and Research Tests for Use in Identifying Specific Cancer Mutations |
| Aug 30, 2021 |
Illumina To Webcast Upcoming Investor Conference |
| Aug 18, 2021 |
Illumina Acquires GRAIL to Accelerate Patient Access to Life-Saving Multi-Cancer Early-Detection Test |
| Aug 5, 2021 |
Illumina Reports Financial Results for Second Quarter of Fiscal Year 2021 |
| Aug 3, 2021 |
Illumina Donates US $1 Million in Sequencing Capabilities for COVID-19 Genomic Surveillance in India |
| Jul 28, 2021 |
Illumina to Webcast Upcoming Investor Conference |
| Jul 22, 2021 |
Illumina is Committed to Bringing Lifesaving GRAIL Test to People Globally as European Review Process Enters Second Phase |
| Jul 13, 2021 |
Illumina to Announce Second Quarter 2021 Financial Results on Thursday, August 5, 2021 |
| Jun 1, 2021 |
Illumina Supports Nationwide Program across Belgium to Assess Whole Genome Sequencing for Developmental Disorders Diagnosis |
| May 27, 2021 |
Illumina To Webcast Upcoming Investor Conference |
| May 17, 2021 |
Illumina Appoints Susan Tousi as Chief Commercial Officer and Dr. Alex Aravanis as Chief Technology Officer, Head of Research and Product Development |
| Apr 29, 2021 |
Illumina To Webcast Upcoming Investor Conference |
| Apr 29, 2021 |
Illumina Files Action for Annulment of European Commission’s Decision Asserting Jurisdiction to Review GRAIL Acquisition |
| Apr 28, 2021 |
Illumina to Donate US $60 Million in Sequencing Capabilities to Establish a Global Pathogen Genomics Initiative |
| Apr 27, 2021 |
Illumina Reports Financial Results for First Quarter of Fiscal Year 2021 |
| Apr 22, 2021 |
Illumina and Kartos Therapeutics Announce New Oncology Partnership to Develop an NGS-Based TP53 Companion Diagnostic |
| Apr 20, 2021 |
Illumina Remains Committed to GRAIL Acquisition to Accelerate Access to Breakthrough Multi-Cancer Early Detection Blood Test |
| Apr 5, 2021 |
Illumina Announces Preliminary Revenue for First Quarter Fiscal Year 2021 |
| Mar 30, 2021 |
Illumina Committed to Pursuing GRAIL Acquisition to Accelerate Access to Breakthrough Multi-Cancer Early Detection Blood Test |
| Mar 18, 2021 |
Illumina Announces Board Changes |
| Mar 11, 2021 |
Illumina and Harvard Pilgrim Health Care Real-World Evidence Study Demonstrates Cost-Effectiveness of Offering NIPT to All Pregnant Women |
| Feb 11, 2021 |
Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2020 |
| Feb 10, 2021 |
Illumina to Webcast Upcoming Investor Conference Presentations |
| Feb 8, 2021 |
Illumina Accelerator Invests in Nine Genomics Startups for Second Global Cycle |
| Feb 4, 2021 |
Illumina Supports National Program to Evaluate Potential of Comprehensive Genomic Profiling in Late Stage Cancer Real-World Setting Across Belgium |
| Jan 31, 2021 |
Illumina and Sequoia Capital China Partner to Launch Genomics Incubator in China |
| Jan 25, 2021 |
Illumina to Announce Fourth Quarter & Full Year 2020 Financial Results on Thursday, February 11, 2021 |
| Jan 20, 2021 |
Illumina Wins Patent Infringement Suit against BGI in the UK |
| Jan 11, 2021 |
New Bioinformatics Solution Powers Multi-Omics Discovery at Massive Scale |
| Jan 11, 2021 |
Illumina Announces New and Expanded Oncology Partnerships with Bristol Myers Squibb, Kura Oncology, Myriad Genetics, and Merck to Advance Comprehensive Genomic Profiling |
| Jan 5, 2021 |
Illumina and Helix Collaborate to Assess Prevalence of New SARS-CoV-2 UK Variant (B.1.1.7) in the US and Develop National Surveillance Infrastructure |